Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/TERNS-PHARMACEUTICALS-INC-118621672/news/Terns-Reports-Positive-Top-line-Results-from-Phase-2a-LIFT-Study-of-FXR-Agonist-TERN-101-in-Patients-35598083/?utm_source=whatsapp&utm_medium=social&utm_campaign=share